Table 1.
Demographic and clinical characteristics compared between pre-COVID and during-COVID time periods
| Pre-COVID (N = 376) |
During-COVID (N = 197) |
Total (N = 573) |
p value | |
|---|---|---|---|---|
| Age (at visit) | 0.5491 | |||
| Mean (SD) | 60.5 (13.5) | 59.8 (13.6) | 60.3 (13.5) | |
| Median | 61.5 | 60.0 | 61.0 | |
| Q1, Q3 | 52.0, 69.5 | 50.0, 70.0 | 51.0, 70.0 | |
| Range | (18.0-99.0) | (26.0-87.0) | (18.0-99.0) | |
| Gender | 0.5552 | |||
| F | 373 (99.2%) | 197 (100.0%) | 570 (99.5%) | |
| M | 3 (0.8%) | 0 (0.0%) | 3 (0.5%) | |
| Race | 0.0302 | |||
| White | 351 (93.4%) | 183 (92.9%) | 534 (93.2%) | |
| Black or African American | 7 (1.9%) | 1 (0.5%) | 8 (1.4%) | |
| Asian | 6 (1.6%) | 7 (3.6%) | 13 (2.3%) | |
| American Indian/Alaskan Native | 0 (0.0%) | 3 (1.5%) | 3 (0.5%) | |
| Unknown or not reported | 12 (3.2%) | 3 (1.5%) | 15 (2.6%) | |
| Ethnicity | 0.8353 | |||
| Not Hispanic or Latino | 360 (95.7%) | 187 (94.9%) | 547 (95.5%) | |
| Hispanic or Latino | 10 (2.7%) | 7 (3.6%) | 17 (3.0%) | |
| Unknown or not reported | 6 (1.6%) | 3 (1.5%) | 9 (1.6%) | |
| Distance from facility (miles) | 0.0051 | |||
| N | 368 | 197 | 565 | |
| Mean (SD) | 215.3 (320.0) | 152.7 (207.5) | 193.5 (287.2) | |
| Median | 86.7 | 67.3 | 77.4 | |
| Q1, Q3 | 45.8, 261.7 | 20.9, 197.8 | 35.3, 248.6 | |
| Range | (1.9-2530.1) | (1.9-1225.4) | (1.9-2530.1) | |
| Distance within 100 miles | 0.0193 | |||
| Missing | 8 | 0 | 8 | |
| ≥100 miles | 178 (48.4%) | 75 (38.1%) | 253 (44.8%) | |
| <100 miles | 190 (51.6%) | 122 (61.9%) | 312 (55.2%) | |
| Did patient live in-state? | 0.0943 | |||
| Missing | 8 | 0 | 8 | |
| No | 167 (45.4%) | 75 (38.1%) | 242 (42.8%) | |
| Yes | 201 (54.6%) | 122 (61.9%) | 323 (57.2%) | |
| Did patient live in MN or surrounding 4 states? | 0.0763 | |||
| Missing | 8 | 0 | 8 | |
| No | 83 (22.6%) | 32 (16.2%) | 115 (20.4%) | |
| Yes | 285 (77.4%) | 165 (83.8%) | 450 (79.6%) | |
| Insurance type | 0.2713 | |||
| Missing | 3 | 1 | 4 | |
| Employee | 29 (7.8%) | 21 (10.7%) | 50 (8.8%) | |
| Govt | 123 (33.0%) | 54 (27.6%) | 177 (31.1%) | |
| Private | 221 (59.2%) | 121 (61.7%) | 342 (60.1%) | |
| Method of detection | 0.4723 | |||
| Missing | 11 | 4 | 15 | |
| Imaging detected | 240 (65.8%) | 121 (62.7%) | 361 (64.7%) | |
| Palpable abnormality/symptoms | 125 (34.2%) | 72 (37.3%) | 197 (35.3%) | |
| Bilateral cancer | 0.3393 | |||
| No | 363 (96.5%) | 193 (98.0%) | 556 (97.0%) | |
| Yes | 13 (3.5%) | 4 (2.0%) | 17 (3.0%) | |
| Clinical T category | 0.0874 | |||
| cTis | 68 (18.1%) | 29 (14.7%) | 97 (16.9%) | |
| cT1 | 182 (48.4%) | 92 (46.7%) | 274 (47.8%) | |
| cT2 | 88 (23.4%) | 48 (24.4%) | 136 (23.7%) | |
| cT3 | 28 (7.4%) | 19 (9.6%) | 47 (8.2%) | |
| cT4 | 10 (2.7%) | 9 (4.6%) | 19 (3.3%) | |
| Clinical N category | 0.3124 | |||
| cN0 | 305 (81.1%) | 152 (77.2%) | 457 (79.8%) | |
| cN1 | 53 (14.1%) | 34 (17.3%) | 87 (15.2%) | |
| cN2 | 7 (1.9%) | 3 (1.5%) | 10 (1.7%) | |
| cN3 | 11 (2.9%) | 8 (4.1%) | 19 (3.3%) | |
| Clinical node-positive | 0.2633 | |||
| No | 305 (81.1%) | 152 (77.2%) | 457 (79.8%) | |
| Yes | 71 (18.9%) | 45 (22.8%) | 116 (20.2%) | |
| Clinical M category | >0.992 | |||
| cM0 | 367 (97.6%) | 193 (98.0%) | 560 (97.7%) | |
| cM1 | 9 (2.4%) | 4 (2.0%) | 13 (2.3%) | |
| AJCC 7th edition clinical anatomic stage | 0.1234 | |||
| 0 | 68 (18.1%) | 28 (14.2%) | 96 (16.8%) | |
| I | 170 (45.2%) | 86 (43.7%) | 256 (44.7%) | |
| II | 99 (26.3%) | 55 (27.9%) | 154 (26.9%) | |
| III | 30 (8.0%) | 24 (12.2%) | 54 (9.4%) | |
| IV | 9 (2.4%) | 4 (2.0%) | 13 (2.3%) | |
| AJCC 8th edition clinical prognostic stage | 0.2334 | |||
| 0 | 68 (18.1%) | 28 (14.2%) | 96 (16.8%) | |
| I | 211 (56.1%) | 112 (56.9%) | 323 (56.4%) | |
| II | 65 (17.3%) | 35 (17.8%) | 100 (17.5%) | |
| III | 23 (6.1%) | 18 (9.1%) | 41 (7.2%) | |
| IV | 9 (2.4%) | 4 (2.0%) | 13 (2.3%) | |
| Grade | 0.9184 | |||
| Missing | 2 | 1 | 3 | |
| I | 110 (29.4%) | 54 (27.6%) | 164 (28.8%) | |
| II | 161 (43.0%) | 93 (47.4%) | 254 (44.6%) | |
| III | 103 (27.5%) | 49 (25.0%) | 152 (26.7%) | |
| ER status | 0.3823 | |||
| Missing | 1 | 0 | 1 | |
| Negative | 49 (13.1%) | 31 (15.7%) | 80 (14.0%) | |
| Positive | 326 (86.9%) | 166 (84.3%) | 492 (86.0%) | |
| PR status | 0.6503 | |||
| Missing | 4 | 0 | 4 | |
| Negative | 77 (20.7%) | 44 (22.3%) | 121 (21.3%) | |
| Positive | 295 (79.3%) | 153 (77.7%) | 448 (78.7%) | |
| HER2 status (among patients with invasive breast cancer) | 0.8963 | |||
| Missing | 2 | 3 | 5 | |
| Negative | 266 (86.9%) | 145 (87.3%) | 411 (87.1%) | |
| Positive | 40 (13.1%) | 21 (13.7%) | 61 (12.9%) | |
| Biologic subtype (among patients with invasive breast cancer) | 0.9993 | |||
| Missing | 3 | 3 | 6 | |
| HR+/HER2+ | 30 (9.8%) | 16 (9.6%) | 46 (9.8%) | |
| HR+/HER2- | 234 (76.7%) | 127 (76.5%) | 361 (76.6%) | |
| HR-/HER2+ | 9 (3.0%) | 5 (3.0%) | 14 (3.0%) | |
| HR-/HER2- | 32 (10.5%) | 18 (10.8%) | 50 (10.6%) |
1Wilcoxon
2Fisher Exact
3Chi-Square
4Armitage Trend Test